Profiles of the AI-first biotechs, platform companies, and pharma collaborators shaping AI-driven drug development. Company data compiled from public announcements and verified industry reports.
Clinical-stage generative AI-driven biotech. Its Pharma.AI platform (Biology42 / PandaOmics, Chemistry42, Science42, Generative Biologics, inClinico) covers target discovery through molecule design and clinical-trial prediction.
Industrial-scale phenotypic drug discovery using automated microscopy, CRISPR perturbation, and ~65PB of multi-omics data. Merged with Exscientia in November 2024 to combine high-throughput biology with generative chemistry.
Founded 2021 as a Google DeepMind spin-out to apply AlphaFold and computational methods to drug design. Focuses on computation-led discovery with fewer experimental cycles.
UK-founded AI-first drug design company (2012), acquired by Recursion in Nov 2024. Its Centaur platform pairs generative AI with automated labs in a design-make-test-learn loop; six AI-designed molecules entered clinical trials.
Hybrid physics-based and machine-learning drug discovery platform. LiveDesign is a widely adopted collaborative design environment in pharma.
Uses knowledge graphs and ML for target identification and drug repurposing, with a neurology focus and a long-running AstraZeneca collaboration.
Relay Therapeutics (dynamic protein structure; RLY-2608 PI3Kα in Phase 3), Genesis Therapeutics (geometric deep learning; Genentech/Lilly/Sanofi), Atomwise (deep learning small molecules), Absci (AI biologics; AMD investment), Iktos (AI + robotic synthesis), Generate Biomedicines (generative protein design), Xaira Therapeutics (US$1B seed, 2024), Relay, Verge Genomics, insitro, and ~45 others with active clinical assets.